bioMerieux stock analysis
bioMerieux (EYWN) Stock Price & Analysis
EYWN Stock Chart & Stats
- Day’s Range
- EUR 91.80 - EUR 91.80
- 52-Week Range
- EUR 63.10 - EUR 113.80
- Previous Close
- EUR 91.85
- Volume
- N/A
- Average Volume (3M)
- 44
- Market Cap
- EUR 10.96B
- Enterprise Value
- EUR 7.90B
- Total Cash (Recent Filing)
- EUR 657.70M
- Total Debt (Recent Filing)
- EUR 421.80M
- Price to Earnings (P/E)
- 23.6
- Beta
- 0.52
- Next Earnings
- Feb 26, 2027 (Est.)
- EPS Estimate
- 2.52
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.06%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Low leverage and a substantial equity base reduce financial risk and give bioMérieux flexibility to fund research, product development, and commercial investment. This strengthens resilience through softer demand and supports sustained execution without relying heavily on external financing.
Installed-base Recurring Revenue Model
The combination of installed instruments, recurring consumables, and service revenue creates repeat purchasing tied to customer testing volumes. This platform model can deepen customer relationships, improve revenue visibility, and support durable economics as menus and utilization expand.
Rebounding Free Cash Flow
The sharp free-cash-flow recovery provides more internally generated funding for innovation, capacity, and shareholder or balance-sheet needs. Although consistency still matters, the 2025 step-up demonstrates that the business can convert operations into meaningful cash when conditions normalize.
Bears Say
Recent Revenue Contraction
Recent revenue contraction indicates that bioMérieux’s durable growth engine has temporarily weakened after expansion through 2024. If softer demand persists, slower instrument placements and consumable pull-through could limit operating leverage and reduce resources available for future investment.
Profitability And Return Moderation
Profitability remains positive, but declining net income and lower returns than earlier years show that earnings momentum has cooled. Continued margin or return pressure could reduce the benefit of the company’s installed-base economics and constrain reinvestment despite solid underlying margins.
Inconsistent Cash Conversion
Choppy cash generation makes financial planning less predictable and suggests that reported earnings have not always translated efficiently into cash. Working-capital or other conversion pressure could recur, weakening the funding available for strategic initiatives even after the 2025 recovery.
bioMerieux News
EYWN FAQ
What was bioMerieux’s price range in the past 12 months?
What is bioMerieux’s market cap?
When is bioMerieux’s upcoming earnings report date?
How were bioMerieux’s earnings last quarter?
Is bioMerieux overvalued?
Does bioMerieux pay dividends?
What is bioMerieux’s EPS estimate?
How many shares outstanding does bioMerieux have?
What happened to bioMerieux’s price movement after its last earnings report?
Which hedge fund is a major shareholder of bioMerieux?
What is the TipRanks Smart Score and how is it calculated?
Company Description
bioMerieux
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
- Sector
- General
- Industry
- Medical - Diagnostics & Research
- CEO
- Pierre Boulud
- Employees
- 14,894
- Website
- www.biomerieux.com
- Address
- 376 Chemin De l'Orme, Marcy l'Étoile, ARA, 69280, FR
bioMerieux (EYWN) Earnings & Revenues
EYWN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 6 | 3 |
| Technical Analysis | 4 | 6 | 0 |
| Moving Averages | 9 | 0 | 3 |










